CPA
MXCT icon

Capital Performance Advisors’s MaxCyte MXCT Stock Holding History

Capital Performance Advisors’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12
Closed -$47 – 1738
2024
Q3 		$47 Buy
+12
New +$51 ﹤0.01% 2796

Other funds holding MXCT

CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
RGI
River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital Performance Advisors's MXCT Position: Q4 2024 in Review

Capital Performance Advisors sold out of MaxCyte (MXCT) in Q4 2024, closing a stake of 12 shares — an estimated $47 sold.

Capital Performance Advisors first reported a position in MXCT in Q3 2024 and held it in 1 quarter. The position peaked at $47 in Q3 2024. 119 funds tracked by Wall St. Rank hold MXCT as of Q4 2024.

  • Capital Performance Advisors reported no remaining MaxCyte position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 12 MaxCyte shares in Q4 2024, an estimated $47.
  • Capital Performance Advisors first reported a position in MaxCyte in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's MaxCyte position peaked at $47 in Q3 2024.
  • 119 funds tracked by Wall St. Rank held MaxCyte as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.